Search

Displaying results 4491 - 4500 of 10000 in total
  1. Drug

    Simendan

    go.drugbank.com/drugs/DB12286
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Iobenzamic acid

    go.drugbank.com/drugs/DB13428
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Bucillamine

    go.drugbank.com/drugs/DB12160
    Investigational

    Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

    Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate
  5. Drug

    Tucidinostat

    go.drugbank.com/drugs/DB06334
    Investigational

  6. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  7. Drug

    Sobuzoxane

    go.drugbank.com/drugs/DB21119
    Experimental

    Sobuzoxane is a small molecule drug. The usage of the INN stem '-oxan(e)' in the name indicates that Sobuzoxane is a benzodioxane derivative.

    Categories: Topoisomerase II Inhibitors
  8. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).

  9. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  10. Drug

    SL017

    go.drugbank.com/drugs/DB05156
    Experimental

    SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis